LifeSci Capital analyst Sam Slutsky initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating and $90 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics initiated with a Buy at Truist
- Palvella Therapeutics added to Russell 3000, Russell 2000 Indexes
- Palvella Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Trial and Market Potential
- Palvella Therapeutics completes enrollment in Phase 3 SELVA trial
- Palvella Therapeutics granted sixth U.S. patent covering rapamycin